Compounds, showing selectivity towards COX-2, are
promising agents as selective non-steroidal anti-inflammatory drugs
(NSAIDs) with lower side effects, especially, gastrointestinal ones.
However, recent reports reveal the cardiovascular side effec
ts
associated with the selective COX-2 inhibitors. Therefore, attempts
have been done to develop the second generation of selective COX-2
inheritors. They have safer profile compared to the first generation.
Lumiracoxib belongs to this class of compounds. In this study, the
molecular structure of the target enzymes were prepared. Library of
rationally designed lumiracoxib analogues were docked.
